Cyclosporine A-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: A large multicenter cohort study

Transplantation

Volumn 92, Issue 3, 2011, Pages 334-340

  Castells, Ll ^a   Campos, I ^a   Bilbao, I ^a   Navasa, M ^b   Carrion, J ^b   Forns, X ^b   Berenguer, M ^c   Aguilera, V ^c   Prieto, M ^c   Fernandez I ^d   Meneu, J C ^d   Ulloa, E ^d   Fernandez J R ^e   Suarez M J ^e   Pascasio, J M ^f   Sousa, J M ^f   Casanovas, T ^g   Baliella, C ^g   Barcena R ^h   Rodriguez, M ^h   De La Mata, M ⁱ   Barrera, P ⁱ   Salcedo, M ^j   Banares R ^j   Otero, A ^k   Suarez F ^k   Banos I ^l   Tome S ^m   Herrero, I ⁿ   Guilera, M ^o   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Servicio de Enfermedades Autoinmunes H Clinic   (Spain)

^c H La Fe   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL JUAN CANALEJO   (Spain)

^l HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^m UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

ⁿ UNIVERSITY CLINIC OF NAVARRA   (Spain)

^o Novartis Pharmaceutical SA   (Spain)

more..

Author keywords

Antiviral treatment; HCV; Immunosuppression; SVR

Indexed keywords

ANTIVIRUS AGENT; CYCLOSPORIN A; ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; AGE; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; PRIORITY JOURNAL; PROTECTION; RECURRENCE RISK; RECURRENT VIRUS INFECTION; RETROSPECTIVE STUDY; RISK REDUCTION; SPAIN; SUSTAINED VIRAL RESPONSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 79961028119     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318223d836     Document Type: Article

References (36)

1. European Liver Transplant Registry (ELTR). Registry for the European Liver Transplant Association. Available at: http://www.eltr.org. Accessed November 15, 2010.
2. Wiesner RH, Sorrell M, Villamil F. Report of the First International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1.
3. Berenguer M, Ló pez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666.
4. Fernández I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805.
5. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348.
6. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
7. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679.
8. Carrión JA, Navasa M, García-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132: 1746.
9. Bizollon T, Ahmed S, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283.
10. Gurusamy KS, Tsochatzis E, Xirouchakis E, et al. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010: CD006803.
11. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferonalpha in antiviral regimens for post-transplant recurrent hepatitis C:Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577.
12. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
13. Maluf DG, Edwards EB, Stravitz R, et al. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. Liver Transplant 2009; 15: 592.
14. Segev DL, Maley WR, Simpkins CE, et al. Minimizing risk associated with elderly liver donors by matching to preferred recipients. Hepatology 2007; 46: 1907.
15. Kawaoka T, Hiraga N, Takahashi S, et al. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scand J Gastroenterol 2010; 45: 1488.
16. Ueda Y, Takada Y, Marusaea H, et al. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010; 90: 661.
17. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitisCafter liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100.
18. Samuel D, Roche B. Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: Difficult to manage but essential for success. J Hepatol 2007; 46: 988.
19. Inoue K, Sekiyama K, Yamada M, et al. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: Controlled trial. J Gastroenterol 2003; 38: 567.
20. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006; 12: 51.
21. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: Impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15: 738.
22. Cescon M, Grazi GL, Cucchetti A, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Liver Transpl 2009; 15: 782.
23. Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: Predictors of response and longterm outcome. Transplantation 2009; 88: 1214.
24. Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204.
25. Hirano K, Ichikawa T, Nakao K, et al. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferoninduced antiviral protein in human hepatocyte cells. Liver Transpl 2008; 14: 292.
26. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282.
27. Wainberg MA, Dascal A, Blain N, et al. The effect of cyclosporine A on infection of susceptible cells by human immunodeficiency virus type 1. Blood 1988; 72: 1904.
28. Vahlne A, Larsson PA, Horal P, et al. Inhibition of herpes simplex virus production in vitro by cyclosporin A. Arch Virol 1992; 122: 61.
29. Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067.
30. Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut 2009; 58: 452.
31. Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005; 19: 111.
32. Watashi K. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection. Curr Opin Investig Drugs 2010; 11: 213.
33. Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation 2006; 82: 579.
34. Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13: 1032.
35. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007; 46: 371.
36. Willems M, Metselaar HJ, Tilanus HW, et al. Liver transplantation and hepatitis C. Transpl Int 2002; 15: 61.